| Description |
1 online resource (xi, 222 pages) : illustrations (chiefly color) |
| Contents |
Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients receiving CAR therapy -- Neurotoxicities after CAR-T cell immunotherapy -- Hematologic and non-CRS toxicities -- Response assessment and post-CAR-T cell therapy management -- Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy -- Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas -- CAR T cell therapy for CNS malignancies -- CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer |
| Bibliography |
Includes bibliographical references |
| Notes |
Online resource; title from electronic title page (ClinicalKey, viewed December 19, 2019) |
| Subject |
T cells -- Receptors.
|
|
Tumor antigens.
|
|
Cellular therapy.
|
|
Receptors, Chimeric Antigen -- therapeutic use
|
|
Neoplasms -- therapy
|
|
Immunotherapy, Adoptive
|
|
Receptors, Antigen, T-Cell
|
|
Cell- and Tissue-Based Therapy
|
|
Antigens, Neoplasm
|
|
Cellular therapy
|
|
T cells -- Receptors
|
|
Tumor antigens
|
| Form |
Electronic book
|
| Author |
Lee, Daniel W., editor
|
|
Shah, Nirali, MD, editor.
|
| ISBN |
9780323755979 |
|
0323755976 |
|
